Cargando…

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer

The invasiveness of pancreatic cancer and its resistance to anticancer drugs define its malignant potential, and are considered to affect the peritumoral microenvironment. Cancer cells with resistance to gemcitabine exposed to external signals induced by anticancer drugs may enhance their malignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ono, Hiroaki, Murase, Yoshiki, Yamashita, Hironari, Kato, Tomotaka, Asano, Daisuke, Ishikawa, Yoshiya, Watanabe, Shuichi, Ueda, Hiroki, Akahoshi, Keiichi, Ogawa, Kosuke, Kudo, Atsushi, Akiyama, Yoshimitsu, Tanaka, Shinji, Tanabe, Minoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019754/ https://www.ncbi.nlm.nih.gov/pubmed/36866763 http://dx.doi.org/10.3892/ijo.2023.5499

Ejemplares similares

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells
por: Kato, Tomotaka, et al.
Publicado: (2021)

C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2021)

Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report
por: Murase, Yoshiki, et al.
Publicado: (2020)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer
por: Ishii, Takeshi, et al.
Publicado: (2022)

Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers
por: Murase, Yoshiki, et al.
Publicado: (2021)

Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma
por: Yagi, Kohei, et al.
Publicado: (2023)

Laparoscopic distal pancreatectomy in a patient with aberrant splenic artery originating from the superior mesenteric artery: A case report
por: Ishida, Hiroyuki, et al.
Publicado: (2021)

Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report
por: Matsui, Satoshi, et al.
Publicado: (2021)

MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens
por: Yagi, Kohei, et al.
Publicado: (2023)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma
por: Akasu, Masafumi, et al.
Publicado: (2021)

Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease–related HCC
por: Hatano, Megumi, et al.
Publicado: (2023)

DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma
por: Mizuno, Yuki, et al.
Publicado: (2018)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Comprehensive molecular and immunological characterization of hepatocellular carcinoma
por: Shimada, Shu, et al.
Publicado: (2018)

Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study
por: Kimura, Koichiro, et al.
Publicado: (2020)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Current topics in the surgical treatments for hepatocellular carcinoma
por: Ban, Daisuke, et al.
Publicado: (2018)

Proteasome activity is required for the initiation of precancerous pancreatic lesions
por: Furuyama, Takaki, et al.
Publicado: (2016)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

ECM signals ECM degradation
por: Powell, Kendall
Publicado: (2006)

Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines
por: Grant, Emma, et al.
Publicado: (2022)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2021)

cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer
por: Kabashima, Ayano, et al.
Publicado: (2022)

SOX9 Regulates Multiple Genes in Chondrocytes, Including Genes Encoding ECM Proteins, ECM Modification Enzymes, Receptors, and Transporters
por: Oh, Chun-do, et al.
Publicado: (2014)

Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis
por: Ito, Hiromitsu, et al.
Publicado: (2016)

Structural study of the Fox-1 RRM protein hydration reveals a role for key water molecules in RRM-RNA recognition
por: Krepl, Miroslav, et al.
Publicado: (2017)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

Correction: SOX9 Regulates Multiple Genes in Chondrocytes, Including Genes Encoding ECM Proteins, ECM Modification Enzymes, Receptors, and Transporters
por: Oh, Chun-do, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_imlhnmg3jb0m0jbnflf07l91jd